Paul-Ehrlich-Institut

Information on the Use of Cookies

In order to operate and optimise our website, we would like to collect and analyse statistical information completely anonymously. Will you accept the temporary use of statistics cookies?

You can revoke your consent at any time in our privacy policy.

OK

Glossary

The Paul-Ehrlich-Institut has developed the definitions in this glossary to help users understand regulatory and biomedical terminology. Definitions may differ from those given in German and European Union legislation and medicine. Many definitions correspond to the glossary entries on the pages of the European Medicines Agency (EMA).

TEP - Tissue-Engineered Product

Tissue-Engineered Product (TEP): A medicine containing engineered cells or tissues, which is intended to regenerate, repair or replace a human tissue.

Updated: 21.11.2019

Tumor Vaccines

Tumour vaccines are therapeutic vaccines used to treat cancers. They mediate an immune response against cancer cells. Thus, they differ from prophylactic vaccines for the protection against infectious diseases (e.g., measles, influenza, etc.).

Updated: 21.11.2019

Type IA Variation

A minor change to a marketing authorisation that has a minimal or no impact on the quality, safety or efficacy of the medicine and does not require prior approval before implementation by the marketing authorisation holder.

Updated: 21.11.2019

Type IB Variation

A minor change to a marketing authorisation that the marketing-authorisation holder must notify to the regulatory authority before implementation and that can be implemented within 30 days if no objections have been raised, but which does not require formal approval.

Updated: 21.11.2019

Type II Variation

A major change to a marketing authorisation that may have a significant impact on the quality, safety or efficacy of a medicine, but does not involve a change to the active substance, its strength or the route of administration. Type II variations require a formal approval.

Updated: 21.11.2019